Navigation Links
Cell Therapeutics, Inc. Special Meeting in Lieu of Annual Meeting of Shareholders Scheduled for Tuesday, March 24, 2009

SEATTLE, March 24 /PRNewswire-FirstCall/ -- On Tuesday, March 24, 2009, at 6:00 PM Central European Time/1:00 PM Eastern Time/10:00 AM Pacific Time members of Cell Therapeutics, Inc.'s (CTI) (NASDAQ and MTA: CTIC) management team will host a Special Meeting in lieu of the Annual Meeting of Shareholders at its Seattle headquarters located at 501 Elliott Ave. West, Seattle, WA 98119. The meeting will be webcast live on CTI's website at and archived for replay.

               Special Meeting in lieu of Annual Meeting of Shareholders
                                     Tuesday, March 24

                                      Conference Call

                     10:00 AM Pacific / 1:00 PM Eastern / 6:00 PM CET
                              1-800-218-8862 (US Participants)
                               1-303-228-2960 (International)

                           Call-back numbers for post listening:
                             1-800-405-2236 (US Participants)
                              1-303-590-3000 (International)
                                  Passcode: 11125470#

                               Live webcast with slides at
       Archived for post viewing approximately 2 hours after the meeting ends

    Media Contact:
    Cell Therapeutics, Inc.
    Dan Eramian
    T: 206.272.4343
    C: 206.854.1200
    F: 206.272.4434

    Investors Contact:
    Cell Therapeutics, Inc.
    Ed Bell
    T: 206.272.4345
    Lindsey Jesch
    T: 206.272.4347
    F: 206.272.4434

SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Oxygen Biotherapeutics, Inc. Expands Board of Directors
2. Cell Therapeutics, Inc. (CTI) Reports 2008 Fourth Quarter and Year End Financial Results
3. Cell Therapeutics, Inc. (CTI) to Present at 8th Annual WBBA Invest Northwest Conference
4. Cell Therapeutics, Inc. (CTI) to Report Fourth Quarter and Year-End Financial Results on March 16
5. Cell Therapeutics, Inc. (CTI) BIO CEO Presentation to be Webcast
6. Sopherion Therapeutics, LLC Announces Publication of Phase I/II Myocet(R) (Nonpegylated Liposomal Doxorubicin) Data in Advanced Breast Cancer Patients
7. Cell Therapeutics, Inc. (CTI) to Present at 11th Annual BIO CEO & Investor Conference
8. Cell Therapeutics, Inc. Provides Update on the Special Meeting of Shareholders
9. Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $32.65 Million of Senior Convertible Notes
10. Webcast Alert: Regulus Therapeutics, Alnylam Pharmaceuticals and Isis Pharmaceuticals Announce New Nature Publication on miR-21 Conference Call
11. Cell Therapeutics, Inc. (CTI) Zevalin Joint Venture Conference Call to be Webcast with Slides
Post Your Comments:
(Date:11/25/2015)... ANNAPOLIS, Md. , Nov. 25, 2015  PharmAthene, ... of Directors has adopted a stockholder rights plan (Rights ... its net operating loss carryforwards (NOLs) under Section 382 ... --> --> PharmAthene,s use of its ... an "ownership change" as defined in Section 382 of ...
(Date:11/25/2015)... CITY , Nov. 25, 2015 /PRNewswire/ - Aeterna ... affirms that its business and prospects remain fundamentally ... , Zoptrex™ (zoptarelin doxorubicin) recently received DSMB recommendation ... to completion following review of the final interim ... Phase 2 Primary Endpoint in men with heavily ...
(Date:11/24/2015)... Malaysia , Nov. 24, 2015  Asia-Pacific ... contract research organisation (CRO) market. The trend of ... in lower margins but higher volume share for ... capacity and scale, however, margins in the CRO ... Organisation (CRO) Market ( ), finds ...
(Date:11/24/2015)... ... 2015 , ... Copper is an essential micronutrient that all ... copper is also toxic to cells. With a $1.3 million award from the ... a systematic study of copper in the bacteria Pseudomonas aeruginosa (P. aeruginosa), a ...
Breaking Biology Technology:
(Date:11/4/2015)... ALBANY, New York , November 4, 2015 /PRNewswire/ ... According to a new market report published by Transparency ... Size, Share, Growth, Trends and Forecast 2015 - 2022", ... value of US$ 30.3 bn by 2022. The market ... during the forecast period from 2015 to 2022. Rising ...
(Date:10/29/2015)... ARBOR, Mich. , Oct. 29, 2015 /PRNewswire/ ... Eurofins Genomics for U.S. distribution of its DNA ... DNA-seq kit and Rubicon,s new ThruPLEX Plasma-seq kit. ... to enable the preparation of NGS libraries for ... plasma for diagnostic and prognostic applications in cancer ...
(Date:10/27/2015)... Germany , October 27, 2015 ... SMI,s Automated Semantic Gaze Mapping technology (ASGM) automatically maps ... SMI,s Eye Tracking Glasses , so that they ... BeGaze. --> Munich, Germany , ... (ASGM) automatically maps data from mobile eye tracking videos ...
Breaking Biology News(10 mins):